Shin SU - Search Results

1

A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors.

Penichet ML, Dela Cruz JS, Shin SU, Morrison SL. Penichet ML, et al. Among authors: shin su. Hum Antibodies. 2001;10(1):43-9. Hum Antibodies. 2001. PMID: 11455061

2

An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells.

Ng PP, Dela Cruz JS, Sorour DN, Stinebaugh JM, Shin SU, Shin DS, Morrison SL, Penichet ML. Ng PP, et al. Among authors: shin su, shin ds. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10706-11. doi: 10.1073/pnas.162362999. Epub 2002 Jul 29. Proc Natl Acad Sci U S A. 2002. PMID: 12149472 Free PMC article.

3

In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice.

Penichet ML, Challita PM, Shin SU, Sampogna SL, Rosenblatt JD, Morrison SL. Penichet ML, et al. Among authors: shin su. Lab Anim Sci. 1999 Apr;49(2):179-88. Lab Anim Sci. 1999. PMID: 10331548

4

An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain.

Penichet ML, Kang YS, Pardridge WM, Morrison SL, Shin SU. Penichet ML, et al. Among authors: shin su. J Immunol. 1999 Oct 15;163(8):4421-6. J Immunol. 1999. PMID: 10510383

5

Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein.

Cho HM, Rosenblatt JD, Kang YS, Iruela-Arispe ML, Morrison SL, Penichet ML, Kwon YG, Kim TW, Webster KA, Nechustan H, Shin SU. Cho HM, et al. Among authors: shin su. Mol Cancer Ther. 2005 Jun;4(6):956-67. doi: 10.1158/1535-7163.MCT-04-0321. Mol Cancer Ther. 2005. PMID: 15956253

6

Genetically engineered antibodies and their application to brain delivery.

Morrison SL, Shin SU. Morrison SL, et al. Among authors: shin su. Adv Drug Deliv Rev. 1995 Jul;15(1-3):147-175. Adv Drug Deliv Rev. 1995. PMID: 35524387

7

Genetically engineered antibodies: progress and prospects.

Wright A, Shin SU, Morrison SL. Wright A, et al. Among authors: shin su. Crit Rev Immunol. 1992;12(3-4):125-68. Crit Rev Immunol. 1992. PMID: 1476621 Review.

8

Structural and functional properties of mouse-human chimeric IgD.

Shin SU, Wei CF, Amin AR, Thorbecke GJ, Morrison SL. Shin SU, et al. Hum Antibodies Hybridomas. 1992 Apr;3(2):65-74. Hum Antibodies Hybridomas. 1992. PMID: 1633267

9

Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: potential applications for cellular targeting.

Shin SU, Morrison SL. Shin SU, et al. Proc Natl Acad Sci U S A. 1990 Jul;87(14):5322-6. doi: 10.1073/pnas.87.14.5322. Proc Natl Acad Sci U S A. 1990. PMID: 2115168 Free PMC article.

10

Transferrin-antibody fusion proteins are effective in brain targeting.

Shin SU, Friden P, Moran M, Olson T, Kang YS, Pardridge WM, Morrison SL. Shin SU, et al. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2820-4. doi: 10.1073/pnas.92.7.2820. Proc Natl Acad Sci U S A. 1995. PMID: 7708731 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

363 results

Search Page

Filters